


## Treatment-Naive Genotype 1b Without Cirrhosis

Recommended regimens listed by evidence level and alphabetically for:

### Treatment-Naive Patients Genotype 1b Without Cirrhosis

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg)	12 weeks <sup>a</sup>	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup>	8 weeks	I, A
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks	I, A
<hr/>		
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for patients who are HIV-uninfected and whose HCV RNA level is <6 million IU/mL	8 weeks <sup>c</sup>	I, B
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A

<sup>a</sup> An 8-week regimen can be considered in those with genotype 1b infection and mild fibrosis (see text for details).

<sup>b</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

<sup>c</sup> For HIV/HCV coinfecting patients, a treatment duration of 12 weeks is recommended.

**Last update:** August 27, 2020